Emerging data suggest Retatrutide , a dual activator targeting both GLP-1 and another hormone, may represent a significant step forward for weight management . Preliminary clinical trials have indicated substantial decreases in abdominal fat , potentially outperforming other body composition treatments. However , further study is needed to fully de